Holen Sie sich die Stockscreener-App
28.29
2.04%
-0.69
Schlusskurs vom Vortag:
$28.98
Offen:
$28.38
24-Stunden-Volumen:
10.98M
Relative Volume:
0.34
Marktkapitalisierung:
$6.55B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
54.19
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+3.20%
1M Leistung:
+0.42%
6M Leistung:
-25.05%
1J Leistung:
-48.62%
1-Tages-Spanne:
$28.07
$29.75
1-Wochen-Bereich:
$25.40
$29.82
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
28.30 | 6.71B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
15.72 | 49.67B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.11 | 40.26B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 40.11B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.34 | 34.46B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
542.54 | 23.48B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers (HIMS) Stock: Investors Reassess Growth Path in Digital Health Weight-Loss Push - parameter.io
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz - The National Law Review
Why Hims & Hers Stock Jumped Today as Its Weight-Loss Bet Gets a Second Look - TechStock²
Hims & Hers Health Jumps 5.0% Amid Sector-Wide Rally - AlphaStreet
Hims & Hers Stock Edges Higher: What's Going On? - Benzinga
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating - Moomoo
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.7% R - GuruFocus
HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks - Stocktwits
Investors heavily search Hims & Hers Health, Inc. (HIMS): Here is what you need to know - MSN
HIMS Stock Eyes 2-Week Green Streak: Analyst Sees Nearly 20% Upside On Multi-Year Opportunity In Peptides - Stocktwits
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat - Stocktwits
Investor relations - HIMS Investor Relations
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers H - The National Law Review
PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today - TradingKey
Hims & Hers Health Stock (HIMS) Opinions on Biotech Sector Momentum - Quiver Quantitative
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Insider Monkey
HIMS vs. TEM: Which AI healthcare stock offers better upside now? - MSN
Hims & Hers Health Options Spot-On: On June 1st, 185.47K Contracts Were Traded, With 1.08 Million Open Interest - Moomoo
Hims & Hers Health, Inc. Class A Trade Ideas — XETR:82W - TradingView
Hims & Hers Health Options Spot-On: On June 3rd, 96,548 Contracts Were Traded, With 1.06 Million Open Interest - Moomoo
How Investors Are Reacting To Hims & Hers Health (HIMS) Hiring a Longevity-Focused Chief Medical Officer - simplywall.st
HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded - Stocktwits
Hims & Hers Health Options Spot-On: On June 5th, 153.61K Contracts Were Traded, With 1.08 Million Open Interest - Moomoo
Hims CMO Appointment Highlights Longevity Focus And Raises Valuation Questions - Yahoo Finance
Hims & Hers Stock Closes Eucalyptus Deal With a $20 Billion Peptide Bet on Deck. Here’s What to Expect - TIKR.com
Hims & Hers expands UK footprint with Eucalyptus acquisition - Pharmacy Business
What is behind Hims & Hers Health stock's recent drop in value today - Traders Union
Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock - The Globe and Mail
Hims & Hers Health stock price forecast: $34.06 resistance as HIMS climbs 1.82% - Traders Union
HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform - Stocktwits
HIMS Stock | Hims & Hers Health, Inc. Price, Quote, News & Analysis - TipRanks
Hims & Hers Health Jumps 7.0% Amid Sector-Wide Rally - AlphaStreet
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims - Hims & Hers Newsroom
Price-Driven Insight from (HIMS) for Rule-Based Strategy - Stock Traders Daily
Hims & Hers Names Anant Vinjamoori Chief Medical Officer of Hims Brand - INDIA New England News
Hims & Hers Stock Jumps: What's Happening Today? - Benzinga
$Hims & Hers Health (HIMS.US)$ Never expect the rise on bad day and forgot to cancel my 1 week GTD[Hurt][Hurt][Hurt] - Moomoo
Why is Hims & Hers Health stock rallying today? By Investing.com - Investing.com Canada
Hims & Hers appoints Dr. Anant Vinjamoori as chief medical officer - Investing.com Canada
Hims & Hers Health stock consolidates as price holds between $25.61 and $29.41 - Traders Union
1 Growth Stock Set to Flourishand 2 We Ignore - The Globe and Mail
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Most and least shorted mid- to mega-cap healthcare stocks at the end of May - Seeking Alpha
Canaccord reiterates Hims & Hers stock Buy rating on peptide growth - Investing.com
Taking A Fresh Look At Hims & Hers Health (HIMS) Valuation After Recent Share Price Swings - Yahoo Finance
Political Scrutiny Tests Hims And Hers GLP1 Weight Loss Growth Story - Yahoo Finance
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):